Advertisement
Screener

Generate Biomedicines, Inc. (GENB) Payments to Acquire Marketable Securities

2.8 / 5 stars · 68/120 Roast Me

Generate Biomedicines, Inc. Payments to Acquire Marketable Securities

Generate Biomedicines, Inc. (GENB) reported Payments to Acquire Marketable Securities of $321.76 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Cash Flow › Investing Activities

us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-06

  • Generate Biomedicines, Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $606.00K, a 99.07% decline year-over-year.
  • Generate Biomedicines, Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $321.15M, a 315.19% increase year-over-year.
  • Generate Biomedicines, Inc. payments to acquire marketable securities for the quarter ending 2025-06-30 was $65.16M.
  • Generate Biomedicines, Inc. payments to acquire marketable securities for the quarter ending 2025-03-31 was $77.35M.
Period endPayments to Acquire Marketable Securities 3 monthPayments to Acquire Marketable Securities 6 month
2026-06-30$606.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
$321.76M
10-Q · filed 2026-08-06
2026-03-31$321.15M
10-Q · filed 2026-05-07
2025-06-30$65.16M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
$142.51M
10-Q · filed 2026-08-06
2025-03-31$77.35M
10-Q · filed 2026-05-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
PERRIGO Co plc (PRGO)Ireland$2.038B-0.79
NEKTAR THERAPEUTICS (NKTR)United States$2.026B-9.05
UroGen Pharma Ltd. (URGN)$2.015B-18.42
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
Nuvation Bio Inc. (NUVB)United States$2.007B-13.12
PALVELLA THERAPEUTICS, INC. (PVLA)United States$2.105B-35.55
Braveheart Bio, Inc. (BRVE)United States$2.106B
Bausch Health Companies Inc. (BHC)$2.113B-1.68
Biohaven Ltd. (BHVN)United States$1.990B-3.83
AGIOS PHARMACEUTICALS, INC. (AGIO)United States$1.962B-5.38